Pharvaris N.V. PHVS

$31.55 -0.73 (-2.26%)

Valuation

Market cap
2,111,370,000
Revenue TTM
$0
Net income TTM
$-198,790,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
390,100
Avg volume
690,758
Day's range
$31.22 – $32.63
Shares out
65,408,000
Stochastic %K
8%
Beta
-2.48
Analysts
Strong Buy
Price target
$59.92

Price

Company profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema du...

Show more

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Industry
Biotechnology
Sector
Healthcare
Phone
31 712036410
Website
https://pharvaris.com
Address
Grafenauweg 8, Zug, Switzerland

Latest news

Stocktwits

De_Monitor Nov 14, 8:36 AM
$PHAR INVESTORS should watch $PHVS and $NTLA closely. Pharvaris is advancing a highly effective oral treatment for HAE attacks, while Intellia’s revolutionary one-time CRISPR therapy has shown sustained results for up to FOUR YEARS. Both face major regulatory milestones and could seriously disrupt the market Ruconest depends on. Two different technologies, one enormous threat to Pharming’s core business. Here’s the problem: Ruconest still generates approximately 80% of Pharming’s quarterly revenue. It’s the company’s only major revenue pillar, with Joenja still too small to offset a substantial decline. Pharvaris could replace injections with convenient pills, while Intellia could dramatically reduce the need for lifelong HAE medication. Regulatory approval and commercial success aren’t guaranteed, but the threat is increasingly real. The question is no longer whether Ruconest faces serious competition, but how much of its market will survive. $PHVS $NTLA
0 replies
De_Monitor Nov 14, 8:26 AM
$PHVS is shaping up to be one of the most compelling late-stage HAE stories. Its once-daily oral deucrictibant XR cut HAE attacks by 83% versus placebo in Phase 3 CHAPTER-3 (87% in Type 1/2), meeting the primary and every secondary efficacy endpoint with statistical significance. With a generally well-tolerated profile, the prospect of highly effective, injection-free prevention is genuinely exciting. And the momentum doesn’t stop there. Deucrictibant IR delivered a median time to onset of symptom relief of just 1.28 hours in RAPIDe-3 and is already under FDA review, with a decision date of April 23, 2027. Add €283M in cash at September 30, upcoming CREAATE data in Q1 2027, and a planned prophylaxis filing in H1 2027. Approval is not guaranteed, but with two oral formulations and multiple major catalysts ahead, the $PHVS bull case keeps getting stronger!
0 replies
outlawinvestor1 Nov 13, 12:24 AM
$PHVS i predict a bidding war for this company soon. buyout target increased to $4.5-6.5B+. https://ir.pharvaris.com/static-files/1f0b0ce0-7a07-4247-a0bb-06d4465ee13a
1 replies
Merlintrader Nov 12, 6:02 PM
$PHVS Latest company news, Nov 12: at ACAAI, Pharvaris reported Phase 3 CHAPTER-3 data for once-daily deucrictibant XR 40 mg, with an 83% reduction in HAE attack rate versus placebo. The late-breaking oral presentation is on Nov 14. Free Merlintrader newsletter, catalysts and FDA dates in your inbox: https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=phvs Full $PHVS stock hub: https://www.merlintrader.com/pharvaris-stock-hub/ Not investment advice.
0 replies
Rayvio_News_Filter Nov 12, 3:30 PM
$PHVS 🏥 Pharvaris announced Phase 3 CHAPTER-3 results showing deucrictibant XR met primary and all secondary endpoints, reducing monthly HAE attack rate by 83% overall and 87% in HAE Type 1/2 versus placebo, with data to be presented at ACAAI 2026. Timely market event More market highlights: https://rayvio.app/dashboard/?utm_source=lifatpt
0 replies
GTA_Terminal Nov 9, 1:54 PM
Dark pool check on $PHVS: what traded off the exchanges in the latest session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Read the full article for the full details: https://globaltradersacademy.com/articles/pharvaris-phvs-technical-levels-options-flow-dark-pools-line-up-above-33-36?utm_source=stocktwits&utm_medium=social
0 replies
DontBanMeAgain Oct 29, 11:28 PM
$BCRX We all own BCRX shares. Question: Is it time to short $PHVS ? After the presentation in a couple weeks, their fledgling therapy won't be looking so exciting. Pick your puts....
2 replies
De_Monitor Oct 24, 7:41 AM
$PHVS 5 months to go!
0 replies